Article2007

Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study

63 citations0/0 files storedEuropean Psychiatry

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes Treatment of Major Depression Medicinal Plant Extracts Effects

Abstract

OBJECTIVE: Anxiety disorders are highly prevalent in population of European countries. However, the effect of Valproate (depakine-chrono) on generalized anxiety disorder (GAD) has not been studied in a double-blind placebo-controlled design. METHOD: Eighty patients (all men) were washout from the all medications. Each patient was randomized to receive either depakine-chrono (40 patients) for 6 weeks or matched placebo (40 patients) in a double-blind manner. Eligible participants, in addition to meeting the DSM-IV criteria for GAD and having a minimum score of 25 and more on the Hamilton Anxiety Scale, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Hamilton anxiety scale score. Response and side effects with depakine-chrono and placebo were compared by using analysis of variance (ANOVA) and chi-square tests. Six patients did not return for at least one subsequent assessment, leaving 74 patients (36 taking depakine-chrono and 38 taking placebo) in the valuables study group. RESULTS: Twenty six of the 36 depakine-chrono-treated participants responded by 6 weeks, versus six of the 38 placebo-treated participants (p<0.001). The most common and problematic side effect in the depakine-chrono group was dizziness and nausea. CONCLUSIONS: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of a depakine-chrono in the management of anxiety disorders. They need to be replicated in a larger study group.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 63 citations exist upstream.

References

1959THE ASSESSMENT OF ANXIETY STATES BY RATING 2005Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies 2005Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology 1997The Cross-national Epidemiology of Panic Disorder 2004Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder 1992Valproate and Carbamazepine in the Treatment of Panic and Posttraumatic Stress Disorders, Withdrawal States, and Behavioral Dyscontrol Syndromes 1996Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs.1994Panic disorder: treatment with valproate.

Cited by

2019Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis 2011Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines.2018Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.